Walleye Capital LLC Purchases New Stake in LifeMD, Inc. $LFMD

Walleye Capital LLC purchased a new stake in shares of LifeMD, Inc. (NASDAQ:LFMD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 323,898 shares of the company’s stock, valued at approximately $1,338,000. Walleye Capital LLC owned 0.67% of LifeMD as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of LifeMD by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after acquiring an additional 2,235 shares during the period. Creative Planning bought a new stake in shares of LifeMD in the second quarter worth about $272,000. JPMorgan Chase & Co. grew its stake in shares of LifeMD by 581.2% in the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Legal & General Group Plc grew its stake in shares of LifeMD by 187.4% in the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after purchasing an additional 6,614 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in LifeMD by 8.7% during the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after purchasing an additional 4,281 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Price Performance

LFMD stock opened at $3.45 on Friday. LifeMD, Inc. has a 1 year low of $2.56 and a 1 year high of $7.32. The firm has a 50-day moving average of $4.26 and a 200 day moving average of $3.96. The company has a market cap of $166.29 million, a P/E ratio of -68.99 and a beta of 2.02.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. On average, equities research analysts expect that LifeMD, Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

LFMD has been the subject of a number of recent analyst reports. HC Wainwright lowered their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, August 7th. B. Riley Financial cut their price objective on LifeMD from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. BTIG Research reduced their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. UBS Group restated a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of LifeMD in a research note on Tuesday, August 4th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Key Headlines Impacting LifeMD

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate slightly to $(0.46) from $(0.47), increased its Q4 2026 estimate to $0.06 from $0.02, and improved its Q1 2027 estimate to $(0.07) from $(0.09). These revisions suggest the analyst sees some near-term improvement in profitability.
• Positive Sentiment: The continued Buy rating and $9.00 target indicate HC Wainwright believes LifeMD’s long-term valuation and growth prospects remain attractive despite ongoing losses.
• Neutral Sentiment: HC Wainwright projects LifeMD will remain unprofitable in FY2026, with estimated EPS of $(0.46), before losses narrow to $(0.12) in FY2027. The forecast implies a gradual recovery rather than immediate sustained profitability.
• Negative Sentiment: The analyst cut its Q3 2026 EPS estimate sharply to $(0.15) from $(0.05), signaling expectations for weaker near-term results.
• Negative Sentiment: Forecasts for Q2 2027 and Q3 2027 were reduced to $(0.13) and $(0.09), respectively, while the FY2027 estimate fell substantially to $(0.12) from $(0.01). The broader downward revision suggests profitability may take longer to achieve than previously expected.

LifeMD Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.